Stock LGVN LONGEVERON INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Longeveron Inc.

Equities

LGVN

US54303L2034

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
1.75 USD +4.79% Intraday chart for Longeveron Inc. -8.85% -87.13%
04-15 Top Premarket Gainers MT
04-08 Top Premarket Gainers MT

Business Summary

Longeveron Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The Company is primarily focused on three pipeline indications, which include Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty. Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The Company has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.

Number of employees: 24

Sales per Business

USD in Million2022Weight2023Weight Delta
Biological Solutions
100.0 %
0 100.0 % 0 100.0 % -85.46%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 100.0 % 0 100.0 % -85.46%

Managers

Managers TitleAgeSince
Mohamed Wa’el Ahmed Hashad CEO
 Chief Executive Officer 61 28/02/23
Joshua Hare FOU
 Founder 61 08/10/14
Lisa Locklear DFI
 Director of Finance/CFO 64 30/07/23
Nataliya Agafonova CTO
 Chief Tech/Sci/R&D Officer 55 30/06/23
Kevin Ramdas CTO
 Chief Tech/Sci/R&D Officer - 31/10/19
Jerome Bailey COO
 Chief Operating Officer - 14/09/22
Brian Rash CTO
 Chief Tech/Sci/R&D Officer - 10-31
Anthony Oliva PRN
 Corporate Officer/Principal 53 31/12/14
Paul Lehr LAW
 General Counsel 56 31/12/15
Lisa McClain Moss PRN
 Corporate Officer/Principal 53 31/12/16

Members of the board

Members of the board TitleAgeSince
Joshua Hare FOU
 Founder 61 08/10/14
Jeffrey Pfeffer BRD
 Director/Board Member 77 08/06/23
Cathy Ross BRD
 Director/Board Member 56 11/02/21
Mohammed Khoso Baluch BRD
 Director/Board Member 66 08/06/23
Douglas Losordo BRD
 Director/Board Member 65 11/02/21
Mohamed Wa’el Ahmed Hashad CEO
 Chief Executive Officer 61 28/02/23
Neil Hare BRD
 Director/Board Member 54 31/08/15
Rock Soffer BRD
 Director/Board Member 42 29/02/20
Ursula Ungaro BRD
 Director/Board Member 73 31/05/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,484,005 0 0 56.43 %
Stock B 1 3,314,020 2,707,433 ( 81.70 %) 0

Shareholders

NameEquities%Valuation
Rock Soffer
20.26 %
208,534 20.26 % 677 736 $
Armistice Capital LLC
17.83 %
183,600 17.83 % 596 700 $
Joshua Hare
17.73 %
182,588 17.73 % 593 411 $
Mohamed Wa’el Ahmed Hashad
1.905 %
19,616 1.905 % 63 752 $
Vanguard Group, Inc. (Subfiler)
1.855 %
19,098 1.855 % 62 069 $
Donald Soffer
1.540 %
15,851 1.540 % 51 516 $
Paul Lehr
1.206 %
12,420 1.206 % 40 365 $
BlackRock Institutional Trust Co. NA
1.077 %
11,087 1.077 % 36 033 $
Creative Planning LLC
1.062 %
10,932 1.062 % 35 529 $
Geode Capital Management LLC
0.8765 %
9,024 0.8765 % 29 328 $
NameEquities%Valuation
Joshua Hare
51.30 %
7,612,902 51.30 % 76 $
Ds Med LLC
44.04 %
6,535,223 44.04 % 65 $
Rock Soffer
2.763 %
410,094 2.763 % 4 $

Company contact information

Longeveron, Inc.

Life Science & Technology Park 1951 Northwest 7th Avenue

33136, Miami

+

http://www.longeveron.com
address Longeveron Inc.(LGVN)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.75 USD
Average target price
30.05 USD
Spread / Average Target
+1,617.14%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
LONGEVERON INC. Stock Longeveron Inc.
-87.13% 12.6M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. LGVN Stock
  4. Company Longeveron Inc.